Valuation: Stereotaxis, Inc.

Capitalization 185M 157M 144M 136M 254M 17.49B 256M 1.71B 666M 8.4B 695M 680M 29.01B P/E ratio 2026 *
-9.83x
P/E ratio 2027 * -15.4x
Enterprise value 185M 157M 144M 136M 254M 17.49B 256M 1.71B 666M 8.4B 695M 680M 29.01B EV / Sales 2026 *
4.57x
EV / Sales 2027 * 3.44x
Free-Float
84.59%
Yield 2026 *
-
Yield 2027 * -
1 week-1.55%
Current month+1.60%
1 month-2.56%
3 months-10.38%
6 months-30.15%
Current year-17.39%
1 week 1.85
Extreme 1.85
2
1 month 1.76
Extreme 1.76
2.12
Current year 1.74
Extreme 1.74
2.86
1 year 1.74
Extreme 1.74
3.59
3 years 1.33
Extreme 1.33
3.59
5 years 1.33
Extreme 1.33
10.3
10 years 0.47
Extreme 0.47
10.3
Manager TitleAgeSince
Chief Executive Officer 59 03/02/2017
Director of Finance/CFO 57 01/10/2019
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 79 01/02/2005
Chairman 59 03/02/2017
Director/Board Member 71 29/09/2016
Change 5d. change 1-year change 3-years change Capi.($)
0.00%-1.55%-10.80%+9.83% 185M
-1.99%-0.90%+15.35%-13.03% 173B
-0.76%-1.69%-16.11%+49.25% 159B
-2.56%-2.28%-9.79%-27.22% 121B
-4.67%-4.55%-47.57%+1.58% 80.16B
-3.38%-4.79%+8.52%-9.85% 46.04B
-0.85%-3.56%-28.52%-40.48% 44.18B
+1.32%+15.63%+3.22%+28.32% 34.86B
-2.55%+0.96%+8.13%-9.21% 32.67B
+0.06%+1.31%-23.83%-43.92% 30.34B
Average -1.54%-0.10%-10.14%-5.47% 72.18B
Weighted average by Cap. -1.91%-1.07%-8.49%-0.63%

Financials

2026 *2027 *
Net sales 40.5M 34.41M 31.49M 29.72M 55.44M 3.82B 55.93M 374M 146M 1.84B 152M 149M 6.34B 53.85M 45.75M 41.87M 39.52M 73.72M 5.09B 74.37M 497M 194M 2.44B 202M 198M 8.43B
Net income -17.38M -14.76M -13.51M -12.75M -23.78M -1.64B -23.99M -160M -62.47M -788M -65.19M -63.81M -2.72B -10.62M -9.03M -8.26M -7.8M -14.54M -1B -14.67M -98M -38.2M -482M -39.86M -39.02M -1.66B
Net Debt - -
Logo Stereotaxis, Inc.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
Employees
131
Date Price Change Volume
08/05/26 1.900 $ 0.00% 330,285
07/05/26 1.900 $ -1.04% 295,320
06/05/26 1.920 $ 0.00% 299,973
05/05/26 1.920 $ +1.05% 241,015
04/05/26 1.900 $ -1.55% 189,860
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.900USD
Average target price
4.250USD
Spread / Average Target
+123.68%

Quarterly revenue - Rate of surprise